Trial · NCT00464620
Results by group39
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 39
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate: Number of Participants With Objective Tumor Response | GIST: Dasatinib, 70 mg, Twice Daily | 12 | Participants | ||
| Response Rate: Number of Participants With Objective Tumor Response | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | 14 | Participants | ||
| Response Rate: Number of Participants With Objective Tumor Response | Indolent Subtype: Dasatinib, 70 mg, Twice Daily | 20 | Participants | ||
| 6 Month Progression-free Survival Rate of Indolent Sarcomas Treated With Dasatinib | Indolent Subtypes: Dasatinib, 70 mg, Twice Daily | 52 | Participants | ||
| 6 Month Progression-free Survival Rate of Gastrointestinal Stromal Tumors (GIST) | GIST: Dasatinib, 70 mg, Twice Daily | 14 | Participants | ||
| Median Time-to-progression of Subjects With GIST Treated With Dasatinib. | GIST: Dasatinib, 70 mg, Twice Daily | 2.9 | Full Range 2 to 5.5 | months | |
| Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib. | GIST: Dasatinib, 70 mg, Twice Daily | 2 years overall survival | 21 | Participants | |
| Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib. | Indolent Subtype: Dasatinib, 70 mg, Twice Daily | 2 years overall survival | 48 | Participants | |
| Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib. | GIST: Dasatinib, 70 mg, Twice Daily | 5 years overall survival | 8 | Participants | |
| Overall Survival Rates at 2 and 5 Years From Registration of Subjects Treated With Dasatinib. | Indolent Subtype: Dasatinib, 70 mg, Twice Daily | 5 years overall survival | 14 | Participants | |
| Median Time-to-progression of Subjects With Indolent Sarcomas Treated With Dasatinib. | Indolent Subtype: Dasatinib, 70 mg, Twice Daily | 5.8 | Full Range 3.7 to 7.4 | months | |
| 6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype. | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | UPS | 6 | Participants | |
| 6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype. | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | Leiomyosarcoma | 5 | Participants | |
| 6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype. | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | Osteosarcoma | 5 | Participants | |
| 6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype. | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | Rhabdomyosarcoma | 0 | Participants | |
| 6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype. | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | Ewing's Sarcoma | 1 | Participants | |
| 6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype. | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | Liposarcoma | 0 | Participants | |
| 6 Month Progression-free Survival Rate of Subjects Enrolled in the Aggressive Subtype. | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | MPNST | 0 | Participants | |
| Median Time-to-progression of Subjects Enrolled in the Aggressive Subtype. | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | 1.9 | Full Range 0.9 to 2.2 | months | |
| Overall Survival Rates at 2 and 5 Years From Registration of Subjects Enrolled in the Aggressive Subtype Treated With Dasatinib. | Aggressive Subtypes: Dasatinib, 70 mg, Twice Daily | Ewing's Sarcoma : 2 year overall survival rate | 7 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00464620/results